Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epirubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.95 |
| ▸ | MEN1 | O00255 | 10/20 | 0.95 |
| ▸ | THRB | P10828 | 10/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.95 |
| ▸ | BLM | P54132 | 9/20 | 0.95 |
| ▸ | RECQL | P46063 | 8/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.95 |
| ▸ | MAPT | P10636 | 7/20 | 0.95 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.95 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.95 |
| ▸ | BRCA1 | P38398 | 6/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.95 |
| ▸ | HTT | P42858 | 5/20 | 0.95 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.95 |
| ▸ | STAT6 | P42226 | 4/20 | 0.95 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.95 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.95 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epirubicin SCHEMBL18263941 | 1.00 | MEN1 (0.95) | MEN1THRBKMT2ABLMRECQL | |
| Doxorubicin SCHEMBL147967 | 1.00 | MEN1 (0.95) | MEN1THRBKMT2ABLMRECQL | |
| Doxorubicin SCHEMBL28086230 | 0.99 | MEN1 (0.95) | MEN1THRBKMT2ABLMRECQL | |
| Doxorubicin SCHEMBL23753547 | 0.99 | MEN1 (0.95) | MEN1THRBKMT2ABLMRECQL | |
| Doxorubicin SCHEMBL4019285 | 0.99 | MEN1 (0.95) | MEN1THRBKMT2ABLMRECQL | |
| Doxorubicin SCHEMBL28183637 | 0.99 | MEN1 (0.92) | MEN1THRBKMT2ABLMRECQL | |
| Doxorubicin SCHEMBL13858183 | 0.99 | MEN1 (0.92) | MEN1THRBKMT2ABLMRECQL | |
| Epirubicin SCHEMBL94408 | 0.99 | MEN1 (0.92) | MEN1THRBKMT2ABLMRECQL | |
| Epirubicin SCHEMBL8183120 | 0.98 | MEN1 (0.92) | MEN1THRBKMT2ABLMRECQL | |
| Epirubicin SCHEMBL21184881 | 0.97 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1997032589-A1 | COMBINATIONS FOR TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | claimed |
| WO-1997032604-A1 | ANTIPROLIFERATIVE COMBINATIONS, CONTAINING RAF-TARGETED OLIGONUCLEOTIDES AND CHEMOTHERAPEUTIC COMPOUNDS | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | claimed |
| CN-106478651-B | Substituted heteroaryl compound and combinations thereof and purposes | 广东东阳光药业有限公司 | 2019-07-09 | — | — | CN | disclosed |
| CN-105367555-B | Substituted heteroaryl compound and combinations thereof and purposes | 广东东阳光药业有限公司 | 2019-06-25 | — | — | CN | disclosed |
| CN-105461694-B | Substituted heteroaryl compound and combinations thereof and purposes | 广东东阳光药业有限公司 | 2019-05-24 | — | — | CN | disclosed |
| CN-106478607-B | Substituted heteroaryl compound and combinations thereof and purposes | 广东东阳光药业有限公司 | 2019-05-24 | — | — | CN | disclosed |
| CN-109776522-A | Substituted heteroaryl compound and combinations thereof and purposes | 广东东阳光药业有限公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-105777756-B | Heteroaryl compound and its application in drug | 广东东阳光药业有限公司 | 2019-03-01 | — | — | CN | disclosed |
| CN-104974162-B | Bicyclic pyrazolone compounds and its application method and purposes | 广东东阳光药业有限公司 | 2018-09-14 | — | — | CN | disclosed |
| CN-104926794-B | Substituted heteroaryl compound and combinations thereof and purposes | 广东东阳光药业有限公司 | 2017-12-05 | — | — | CN | disclosed |
| CN-104926795-B | Substituted heteroaryl compound and combinations thereof and purposes | 广东东阳光药业有限公司 | 2017-11-10 | — | — | CN | disclosed |
| CN-106432246-A | Heteroaromatic compound and application thereof to drug | 广东东阳光药业有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-105777756-A | Heteroaryl compound and application thereof in medicines | 广东东阳光药业有限公司 | 2016-07-20 | — | — | CN | disclosed |
| US-20140274927-A1 | TNF-Related Biomarkers For Assessing Cancer Cell Response To Treatment With Taxane And/Or Anthracycline Drugs | PARISSENTI AMADEO MARK (CA) | 2014-09-18 | — | — | US | disclosed |
| CN-103002895-A | Method for treating hematologic cancers | NIIKI PHARMA INC | 2013-03-27 | — | — | CN | disclosed |
| EP-2274010-A1 | THERAPEUTIC COMBINATIONS OF ANTI-IGF-1R ANTIBODIES AND OTHER COMPOUNDS | Biogen Idec MA Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009126304-A1 | THERAPEUTIC COMBINATIONS OF ANTI-IGF-1R ANTIBODIES AND OTHER COMPOUNDS | BIOGEN IDEC MA INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| EP-0770091-B1 | COMPOUNDS FOR REVERSING DRUG RESISTANCE | SARKADI BALAZS (HU) | 2000-03-01 | — | — | EP | disclosed |
| EP-0770091-A1 | COMPOUNDS FOR REVERSING DRUG RESISTANCE | Sarkadi, Balazs (HU) | 1997-05-02 | — | — | EP | disclosed |
| WO-1995031474-A1 | COMPOUNDS FOR REVERSING DRUG RESISTANCE | SARKADI BALAZS (HU) | 1995-11-23 | — | — | WO | disclosed |